On the stock market since 2024, it operates in the world of health and science. It has 152 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
The cash pile is strong; debt and other items pull the grade toward the middle.
Clearly below the class average.
Clearly below the class average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
An investor who bought at the very peak is down 95% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 8% a year on average.
Sales run at $19.1M a year. A small number, but proof the product has real buyers.
There is $292.3M in the vault; even if every debt were paid off, $291.5M would remain.
A loss of $82.1M against $19.1M in annual sales.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 11/100. For a turnaround signal, the stock first needs to close the gap with the market.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 13/100.
On our five-subject report card, LENZ sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: LENZ is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (13/100) says the stock isn’t cheap.